| tamoxifen / Generic mfg. |
ACTRN12623001131640: Evaluating the Effect of Endocrine Therapy on Gut Bacteria in Estrogen Receptor-Positive Breast Cancer |
|
|
| Not yet recruiting | N/A | 200 | | | Royal North Shore Hospital, Northern Sydney Local Health District- Innovation grant , ANZ Breast Cancer Trials Group (ANZ-BCTG) | Breast cancer, Hot flushes, Anxiety, Join pain and stiffness | | | | |
ChiCTR-TRC-09000625: Randomized Control Trial of Levo-norgestrel Intrauterine System in Women Receiving Tamoxifen for Carcinoma of Breast |
|
|
| Completed | N/A | 120 | | Surveillance (with transvaginal ultrasound scan and outpatient hysteroscopy) for control group against Surveillance (TVS and outpatient hysteroscopy) and intervention with mirena insertion for the intervention group | The Chinese University of Hong Kong; Level of the institution：, Department of Obstetrics and Gynaecology | Carcinoma of Breast on Tamoxifen | | | | |
TEXT-Bone, NCT00963417: Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02 |
|
|
| Active, not recruiting | N/A | 119 | Europe, RoW | laboratory biomarker analysis, dual x-ray absorptiometry | ETOP IBCSG Partners Foundation, National Cancer Institute (NCI), Breast International Group | Breast Cancer, Osteoporosis | 03/11 | 12/25 | | |
NCT00667121: Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline |
|
|
| Active, not recruiting | N/A | 85 | US | citalopram hydrobromide, escitalopram oxalate, gabapentin, sertraline hydrochloride, tamoxifen citrate, venlafaxine, molecular genetic technique, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, adjuvant therapy | Mayo Clinic, National Cancer Institute (NCI) | Breast Cancer, Depression, Hot Flashes, Psychosocial Effects of Cancer and Its Treatment | 05/14 | 12/24 | | |
NCT01658566: Tamoxifen Citrate in Treating Premenopausal Women With Estrogen Receptor-Positive Breast Cancer |
|
|
| Recruiting | N/A | 50 | US | tamoxifen citrate, Nolvadex, TAM, tamoxifen, TMX, polymerase chain reaction, PCR, pharmacological study, pharmacological studies, gene expression analysis, immunohistochemistry staining method, immunohistochemistry, pharmacogenomic studies, Pharmacogenomic Study, matrix-assisted laser desorption/ionization time of flight mass spectrometry, MALDI-TOF Mass Spectrometry, polymorphism analysis, therapeutic conventional surgery, nucleic acid sequencing, Gene Sequencing, Molecular Biology, Nucleic Acid Sequencing, protein analysis | Roswell Park Cancer Institute, National Cancer Institute (NCI) | Estrogen Receptor-positive Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer | 12/16 | | | |
ChiCTR-INR-16007965: Effect of tamoxifen on clinical outcome of patients with thin endometrium undergoing frozen-thawed embryo transfer |
|
|
| Recruiting | N/A | 100 | | tamoxifen ;letrozole | Nanjing General Hospital of Nanjing Military Command; Nanjing General Hospital of Nanjing Military Command, The hospital fund | thin endometrium | | | | |
ChiCTR1800019660: A summary study for the polymorphisms of breast cancer cytochrome P450 family gene and tamoxifen |
|
|
| Recruiting | N/A | 200 | | tamoxifen | Affiliated Cancer Hospital of Harbin Medical University; Affiliated Cancer Hospital of Harbin Medical University, By oneself | Breast cancer patients | | | | |
ChiCTR-IOR-16009045: Clinical Study on Liver-Coursing, Spleen-Strengthening, Resolving Phlegm and Promoting Blood Circulation Therapy for tamoxifen associated fatty liver |
|
|
| Completed | N/A | 260 | | Decoction of Chinese Medicine ;essentiale ;Diet and exercise guidance ;Diet and exercise guidance | Beijing Hospital of TCM Affiliated to Capital Medical University; Beijing Hospital of TCM Affiliated to Capital Medical University, NONE | Tamoxifen associated fatty liver | | | | |
ChiCTR-IOR-17012133: Prospective clinical trial assessing Yu Chai decoction plus tamoxifen as a first line therapy for advanced breast carcinoma |
|
|
| Recruiting | N/A | 100 | | Tamoxifen + placebo group ;Tamoxifen + Yu Chai Decoction | Affiliated Nanhua hospital, University of South China; Affiliated Nanhua hospital, University of South China, Hunan Provincial Science and Technology Dpatment | Breast Cancer | | | | |
ChiCTR1800015719: Ultrasound Diagnosis of Endometrial Hyperplasia After Tamoxifen Therapy in Breast Cancer Women |
|
|
| Recruiting | N/A | 268 | | Hysteroscopic surgery | Beijing Obstetrics and Gynecology Hospital, Capital Medical University; Beijing Obstetrics and Gynecology Hospital, Capital Medical University, The Capital Health Development Research Fund (grant no. 2018-4-2113) | Endometrial disease after endocrinotherapy in breast cancer women | | | | |
NCT04476485: Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy |
|
|
| Recruiting | N/A | 1000 | RoW | endocrine therapy | Shengjing Hospital | Breast Cancer | 12/21 | 12/26 | | |
Treat ER+ight, NCT02753686: Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy |
|
|
| Completed | N/A | 440 | Canada | Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy | Novartis Pharmaceuticals | HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer | 12/22 | 12/22 | | |
NCT05801705: Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study |
|
|
| Not yet recruiting | N/A | 700 | RoW | Aromatase inhibitor, ovarian function suppression (Oophorectomy, Ovarian irradiation, Gonadotropin-releasing hormone agonist), Tamoxifen, toremifene | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Hormone-receptor-positive Breast Cancer, Premenopausal Breast Cancer, Breast Cancer Patients at Intermediate to High Risk, Ovarian Function Suppression Combined With Aromatase Inhibitor or Tamoxifen or Torimefen | 06/23 | 12/23 | | |
NCT04995731: Risk Assessment of Endometrial Hyperplasia and Endometrial Cancer |
|
|
| Recruiting | N/A | 328 | RoW | Information about clinical risk factors for endometrial cancer and endometrial hyperplasia (EH), transvaginal ultrasound examination, power Doppler endometrial vascularity assessment, endometrial sampling | Assiut University | Endometrial Cancer | 07/23 | 07/24 | | |
NEMO, NCT05800197: Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia |
|
|
| Recruiting | N/A | 300 | RoW | Tamoxifen 20mg, Anastrozole 1mg, Letrozole 2.5mg, Goserelin, Triptorelin | Blokhin's Russian Cancer Research Center | Breast Cancer, Neoadjuvant Endocrine Therapy | 08/23 | 01/25 | | |
| Active, not recruiting | N/A | 829 | Europe | Hysteroscopy, Endometrial biopsy | Regina Elena Cancer Institute, University of Palermo, University of Padova, Universita di Verona, Federico II University, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, University of Messina, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | Endometrial Cancer, Endometrial Hyperplasia With Atypia, Breast Cancer, TAM | 09/23 | 01/24 | | |
GEFPICS IHC4, NCT04246606: Concordance of the IHC4 Score Performed in Local or Central Laboratory to Endopredict in ER+/HER2- Breast Cancer |
|
|
| Completed | N/A | 155 | Europe | IHC4 score | UNICANCER, Roche Diagnostics | Breast Neoplasm Female | 09/23 | 11/23 | | |
NCT05056857: Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen |
|
|
| Recruiting | N/A | 290 | US | Biospecimen Collection, Biological Sample Collection, Electronic Health Record Review | M.D. Anderson Cancer Center, National Cancer Institute (NCI), National Institute of Allergy and Infectious Diseases (NIAID) | Breast Carcinoma | 10/24 | 10/24 | | |
NCT03719495: Evaluation of Endocrine Therapy Effects of Host Immunity in Early Stage Breast Cancer |
|
|
| Completed | N/A | 68 | US | | Duke University, United States Department of Defense | Breast Cancer, Estrogen Receptor-positive Breast Cancer, Healthy | 07/23 | 07/23 | | |
NCT06120595: Intervention Study Based on Real-world Data to Improve Quality of Life After Breast Cancer Treatment, the REBECCA-2 Study |
|
|
| Active, not recruiting | N/A | 81 | Europe | REBECCA-assisted intervention 1, REBECCA-assisted intervention 2, Standard follow-up | Helse Stavanger HF | Cancer Related Fatigue | 11/23 | 05/25 | | |
NCT01937052: Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database |
|
|
| Active, not recruiting | N/A | 329 | US | Sample collection, Patient-reported outcomes | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Susan G. Komen Breast Cancer Foundation | Breast Cancer | 01/22 | 12/24 | | |
| Recruiting | N/A | 3000 | Europe | | Institut fuer Frauengesundheit, AGO Breast Study Group e.V., Novartis Pharmaceuticals | Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma | 12/23 | 12/23 | | |
| Completed | N/A | 26 | RoW | Prolonged resistance-type exercise training | Universidad de La Frontera | Breast Cancer Survivors, Postmenopause, Resistance Training | 03/24 | 05/24 | | |
SECCO, NCT06164119: Effects of Diet and Osteopathy on Quality of Life and Inflammation in Breast Cancer Patients Under Hormonal Therapy |
|
|
| Recruiting | N/A | 600 | Europe | manual treatment with osteopathic techniques and nutritional treatment, manual treatment with osteopathic techniques, nutritional treatment | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Breast Cancer | 12/25 | 12/25 | | |
| Active, not recruiting | N/A | 421 | Europe | blood take | University Hospital, Ghent | Postmenopausal Symptoms, Alzheimer Disease | 12/24 | 12/24 | | |
| Active, not recruiting | N/A | 5 | Europe | AndroGel | University Medical Center Groningen | Male Breast Cancer | 10/24 | 10/24 | | |
NCT01788839: Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma |
|
|
| Recruiting | N/A | 400 | US | surveys, Blood draw, Transvaginal ultrasounds | Memorial Sloan Kettering Cancer Center | Breast Cancer, Lymphoma, Hodgkin's Lymphoma | 02/25 | 02/25 | | |
EUTACAM, NCT04740697: Study to Evaluate the Impact of the Use of Alternative and Complementary Therapies on Therapeutic Adherence in Patients Treated With taMoxifen for Early Stage Breast Cancer |
|
|
| Recruiting | N/A | 200 | Europe | Treatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen. | Institut Claudius Regaud | Breast Cancer | 02/26 | 02/26 | | |
CPABC, ChiCTR2000029509: Chidamide for patients with advanced breast cancer: a multi-center, prospective real world study |
|
|
| Not yet recruiting | N/A | 2000 | | Patients who have failed treatment with tamoxifen or aromatase inhibitors: Chidamide and Fulvestrant ;Patients who have not been treated or failed treatment with tamoxifen: Chidamide and aromatase inhibitors ;Triple-negative and Her-2 positive patients: Chidamide and PD-1 or anti-Her-2 treatment | The Fifth Medical Centre of Chinese PLA General Hospital; Harbin Medical University Cancer Hospital, self-raised | advanced breast cancer | | | | |
| Not yet recruiting | N/A | 180 | Europe | Tamoxifen, Letrozole, Letrozole + GnRH | International Research Training Group 2804, German Research Foundation, University Hospital Tuebingen, Uppsala University | Breast Cancer Female, Healthy Female, Menopause, Anti-estrogenic Therapy | 12/25 | 04/26 | | |
NCT05501158: CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population |
|
|
| Active, not recruiting | N/A | 150 | RoW | Tamoxifen | Nalagenetics Pte Ltd, SJH Initiatives, Indonesia University, MRCCC Siloam Hospitals Semanggi | Breast Cancer | 04/24 | 06/24 | | |
NCT06474988: Characterization of Biophysical and Mechanical Parameters on Skin of Breast Cancer Patients |
|
|
| Recruiting | N/A | 150 | Europe | Skin tests | European Institute of Oncology | Breast Cancer, Estrogen Receptor Positive Tumor | 05/25 | 05/25 | | |
NASBP-B-09, NCT06154590: Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor |
|
|
| Not yet recruiting | N/A | 100 | US | Method(s)1 Attribution, anastrazole, Method(s)2 Attribution,, Tamoxifen Citrate, NOLVADEX, L phenylalanine mustard (P), Fluorouracil (f) | DR. DIANE CHISESI NFS. MD. PHD., IRB | Metastatic Breast Cancer, Tumor, Muscle Neoplasms, Chronic Pain | 08/25 | 09/26 | | |
ChiCTR2200066156: Effect on endometrium and safety of mirena in utero in breast cancer patients taking tamoxifen after operation |
|
|
| Not yet recruiting | N/A | 40 | | Placement of mirena in the uterine cavity ;nothing | Xiangyang city XiangZhou district people's hospital; XiangZhou district people's hospital, self-raised | Breast cancer | | | | |
NCT05878314: Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer |
|
|
| Recruiting | N/A | 504 | Europe | | University Hospital Tuebingen, University Hospital Ulm, University Hospital Freiburg | Hormone Receptor Positive HER-2 Negative Breast Cancer | 04/25 | 04/35 | | |
NCT03707340: A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors |
|
|
| Active, not recruiting | N/A | 43 | US | Flibanserin Pill | Memorial Sloan Kettering Cancer Center | Breast Cancer, Hyposexual Desire Disorder | 09/25 | 09/25 | | |
NCT05890287: A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy |
|
|
| Recruiting | N/A | 60 | RoW | Chidamide, exemestane, Fulvestrant, Letrozole, Anastrozole, Tamoxifen | Tianjin Medical University Cancer Institute and Hospital | HR Positive HER2 Negative Advanced Breast Cancer | 05/26 | 10/26 | | |
PROMOTE, NCT03621904: Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer |
|
|
| Recruiting | N/A | 150 | Europe | Hormonal Antineoplastics, Progesterone, Tamoxifen, Aromatase inhibitors | Radboud University Medical Center, Haukeland University Hospital, Maastricht University Medical Center, Brno University Hospital, Holycross Cancer Center Kielce, Medical University of Lublin, Hospital del Mar, Hospital Vall d'Hebron, Royal Cornwall Hospitals Trust, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), The Netherlands Cancer Institute, Canisius-Wilhelmina Hospital, Catharina Ziekenhuis Eindhoven, Erasmus Medical Center, Leiden University Medical Center | Endometrial Cancer Stage III, Endometrial Cancer Stage IV, Endometrial Cancer Recurrent | 10/26 | 09/27 | | |
NCT05460819: Acupuncture for Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer. |
|
|
| Not yet recruiting | N/A | 90 | RoW | Acupuncture treatment, Sham Acupuncture treatment | Nanjing University of Traditional Chinese Medicine, School of Life Science and Technology, Xi'an Jiaotong University | Hot Flashes, Breast Cancer, Acupuncture | 07/27 | 07/27 | | |
NCT05613504: Study of Acupuncture in the Treatment of Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer. |
|
|
| Not yet recruiting | N/A | 90 | RoW | Acupuncture treatment, Sham acupuncture treatment | Nanjing University of Traditional Chinese Medicine, School of Life Science and Technology, Xi'an Jiaotong University, Hanzhong Hospital of Traditional Chinese Medicine, Xiang'an Hospital of Xiamen University, Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine | Hot Flashes, Breast Cancer, Acupuncture | 12/27 | 12/27 | | |
VAB, NCT04293796: Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Systemic Therapy and a Confirmed Pathological Complete Response (pCR) Using Vacuum-assisted Biopsy () and Sentinel Lymph Node Biopsy (SLNB) |
|
|
| Recruiting | N/A | 60 | RoW | Vacuum-assisted biopsy | N.N. Petrov National Medical Research Center of Oncology | Refusal of Breast Surgery in Patients With Breast Cancer With a cCR After NST and a Confirmed Pathological Complete Response (pCR) Using VAB and SLNB | 12/27 | 12/28 | | |
